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Abstract
The antifungal activity of allicin and its synergistic effects with the antifungal agents flucytosine and amphotericin B (AmB)
were investigated in Candida albicans (C. albicans). C. albicans was treated with different conditions of compounds alone
and in combination (allicin, AmB, flucytosine, allicin + AmB, allicin + flucytosine, allicin + AmB + flucytosine). After a 24-hour
treatment, cells were examined by scanning electron microscopy (SEM) and atomic force microscopy (AFM) to measure
morphological and biophysical properties associated with cell death. The clearing assay was conducted to confirm the
effects of allicin. The viability of C. albicans treated by allicin alone or with one antifungal drug (AmB, flucytosine) in addition
was more than 40% after a 24-hr treatment, but the viability of groups treated with combinations of more than two drugs
was less than 32%. When the cells were treated with allicin alone or one type of drug, the morphology of the cells did not
change noticeably, but when cells were treated with combinations of drugs, there were noticeable morphological changes.
In particular, cells treated with allicin + AmB had significant membrane damage (burst or collapsed membranes).
Classification of cells according to their cell death phase (CDP) allowed us to determine the relationship between cell
viability and treatment conditions in detail. The adhesive force was decreased by the treatment in all groups compare to the
control. Cells treated with AmB + allicin had a greater adhesive force than cells treated with AmB alone because of the
secretion of molecules due to collapsed membranes. All cells treated with allicin or drugs were softer than the control cells.
These results suggest that allicin can reduce MIC of AmB while keeping the same efficacy.
Citation: Kim Y-S, Kim KS, Han I, Kim M-H, Jung MH, et al. (2012) Quantitative and Qualitative Analysis of the Antifungal Activity of Allicin Alone and in
Combination with Antifungal Drugs. PLoS ONE 7(6): e38242. doi:10.1371/journal.pone.0038242
Editor: Michael Polymenis, Texas A&M University, United States of America
Received January 2, 2012; Accepted May 2, 2012; Published June 5, 2012
Copyright:  2012 Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by a grant from Kyung Hee University in 2011 (KHU-20110093) and the Seoul Research and Business Development program
(Grant No. CR070054). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sigmoidus@khu.ac.kr (HKP); webhospital@naver.com (MHJ)
. These authors contributed equally to this manuscript.
Introduction
C. albicans, a systemic fungus, is a major cause of morbidity and
mortality in patients immunocompromised as a result of AIDS,
cancer chemotherapy, radiotherapy, organ transplantation, or
bone marrow transplantation [1–2]. To treat C. albicans infections,
the antifungal agents flucytosine and amphotericin B (AmB) are
conventionally used in a clinical setting. However, treatment with
these agents can cause severe side-effects, especially in immuno-
compromised patients or those who receive repeated dosing to
treat recurrent infections. It is preferable to prevent fungal
infections in high-risk patients rather than having to treat them.
The primary preventive method against fungal infection is good
hygiene, such as keeping the skin clean and dry. Several alternative
medicines have gained popularity for the safe and effective
prevention of fungal infections. Extracts from several natural
sources have also been shown to have antifungal activity, including
those from Euphorbia hirta L [3], Eqoul [4], Tribulus terrestris L [5],
and allicin from garlic [6–16].
Among these, allicin has been the most actively investigated
because of its prominent antifungal effects. Allicin is an organic
compound, derived mainly from garlic, which contains sulfur.
When garlic is crushed or damaged, alliin, which exists naturally in
garlic, reacts with the enzyme allinase. Allinase acts as a catalyst to
transform alliin into allicin (diallyl thiosulphinate). Several studies
have demonstrated that pure allicin has strong anti-bacterial and
anti-fungal properties [6–16]. Allicin inhibited both the germina-
tion of spores and the growth of hyphae produced by Candida,
Cryptococcus, and Trichophyton species [6–9]. The concentrations of
ß–lactam antibiotics that inhibited the growth of Staphylococcus spp.
and Pseudomonas aeruginosa were reduced in the presence of allicin
[10–11]. Allicin has also been shown to increase oxidative stress,
reduce glutathione levels, and inhibit biofilm formation in C.
albicans [12–4]. The antimicrobial effects of allicin are related to
the ability of allicin to strongly inhibit thiol-containing enzymes
such as cysteine proteinases, alcohol dehydrogenases, and thior-
edoxin reductases [15]. In addition, it was recently suggested that
allicin could increase the activity of Cu
2+, which is a known
promoter of antimicrobial activity; allicin works by accelerating
the production of endogenous reactive oxygen species (ROS) [16].
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e38242Although, allicin has marked antimicrobial effects, it has limited
clinical applications, because the minimal inhibitory concentration
(MIC) of allicin is relatively high [17]. Therefore, allicin is used
mainly as a supplemental agent to enhance the efficacy of
chemical agents. Our goal in this study was to quantitatively and
qualitatively investigate the antifungal activity of allicin alone and
in combination with antifungal drugs. Our results suggest that
allicin can be used to decrease the doses of antifungal agents
required to inhibit C. albicans growth. Especially, it was observed
significant synergistic effects when allicin used in conjunction with
AmB. By measuring the changes in morphology and biophysical
properties of C. albicans treated with allicin by scanning electron
microscopy (SEM) and atomic force microscopy (AFM), the
antifungal effects of allicin was analyzed quantitatively. By clearing
assay, the effects of allicin were clearly visualized. In addition, we
investigated the activity of allicin in combination with the
antifungal agents, flucytosine and AmB.
Results
The antifungal activities of allicin alone and in combination
with AmB and flucytosine were estimated using a cell viability
assay. Figure 1(a) shows C. albicans viability at various concentra-
tions of allicin ranging from 0 (control) to 5 mg/mL. Cell viability
decreased as the allicin concentration increased, but the rate of
reduction was not significant. When the allicin concentration
increased 10-fold from 0.5 to 5 mg/mL, the reduction in cell
viability was only 24%. The MIC10 of allicin for C. albicans was
therefore determined to be 1 mg/mL. Figure 1(b) shows cell
viability as a function of drug treatment time from 0 (control) to 24
hours with different drugs. The viability of cells treated by allicin
alone or one of the antifungal drugs (AmB, flucytosine) was
relatively high (more than 40% at 24 hr), but that of cells treated
with combinations of allicin and the two drugs (AmB + allicin,
flucytosine + allicin, and AmB + flucytosine + allicin) was relatively
low (less than 32% at 24 hr). In all cases, cell viability showed a
similar dependence on treatment time; viability decreased rapidly
after 6–12 hours and then gradually decreased with longer
treatment. In particular, colonies treated with AmB + allicin and
flucytosine + allicin showed the same viability for all treatment
conditions. The slight increase in viability observed at 24 hours is
due to the budding of new cells from undamaged cells.
The effects of the various antifungal drugs on the morphology of
C. albicans were investigated by two spectroscopic techniques,
namely SEM and AFM. Using SEM images, overall changes in
the morphology of the cells were monitored in the relatively large
area of 50650 mm
2. Figures 2(a)–(d) show images of untreated C.
albicans (control) (a), or C. albicans treated with AmB (b), flucytosine
(c), or allicin (d), respectively. Figures 2(e)–(g) are images of cells
treated with the combinations of AmB + allicin (e), flucytosine +
allicin (f), and AmB + flucytosine + allicin (g). All cells were treated
for 24 hours. No significant morphological changes, such as
deformation or shrinkage, were observed in any of the treatment
groups based on SEM images.
AFM images revealed morphological changes of C. albicans
more clearly than the SEM images because AFM is extremely
high-resolution type of scanning probe microscopy with a
demonstrated resolution in the sub-nanometer range. To increase
the resolution more, all images were measured at the very low
scan speed of 0.2 lines/sec. Representative AFM images of C.
albicans are shown in Figure 3, and the figures are arranged in
the same manner as in Fig. 2. Untreated cells (Fig. 3a) were
intact and had smooth surfaces. Cells treated with AmB showed
some peeling of the outer membrane (Fig. 3b), while cells treated
with flucytosine had collapsed outer membranes (Fig. 3c). In
addition, cells treated with allicin had collapsed membranes
(Fig. 3d), but the changes were not significantly different
compared to cells treated with flucytosine. Cells treated with
the combination of allicin and AmB or flucytosine showed more
damage than expected (Figs. 3e–g). In particular, the membranes
of C. albicans treated with AmB + allicin appeared as if they had
burst or collapsed (Fig. 3e).
We also evaluated the effects of allicin and the two antifungal
agents against C. albicans quantitatively. The results of a clearing
assay with AmB (a), flucytosine (b), allicin (c), AmB + allicin (d),
flucytosine + allicin (e), AmB + flucytosine + allicin (f) are shown in
Fig. 4. The assay was conducted with serial dilutions of
MIC10610
21, MIC10, and MIC90, respectively. In all plates, the
growth inhibitory zone around specific antifungals increased as the
concentration of antifungal agent increased. The size of clearance
zone was measured and the result was summarized in table 1.
Since the clearance zone is not a perfect circle, diameter of the
zone was measured at several directions as indicated in Fig. 4(a).
Then, the values were averaged.
The cell death phase (CDP) of C. albicans was analyzed by using
SEM and AFM images. The CDP was divided into four steps
(CDP0, CDP1, CDP2, and CDP3) according to morphological
changes [18]. The CDP results are listed in Table 2; these results
were obtained by counting the number of cells after a 24-hour
treatment. Because the drug concentration was low (MIC10), many
cells in all groups were at CDP0. Even though cell viability did not
vary much according to the type of drug as shown in Fig. 1, the
detailed CDP of the cells was very different according to the
treatment condition. The result of CDP shows a good agreement
with the clearing assay.
Changes in the biophysical properties of C. albicans induced by
allicin or antifungal drug treatment were investigated by force-
distance (FD) curve measurements using AFM. The adhesive force
and stiffness results obtained from analyzing FD curves are shown
in Figs. 5(a) and (b), respectively. There were obvious changes in
adhesive force according to the treatment conditions. The
adhesive force of all cells treated with allicin or drugs was
decreased compared to that of control cells. However, the amount
the adhesive force was reduced by differed with treatment
condition. The adhesive force of cells treated with AmB and
flucytosine was significantly lower than that of control cells.
However, cells treated with allicin showed only a slight decrease in
adhesive force. Cells treated with AmB + allicin had a higher
adhesive force than cells treated with AmB alone. However, in the
cells treated with flucytosine + allicin, the adhesive force was
slightly decreased compare to that of cells treated with flucytosine
alone. Cells treated with AmB + flucytosine + allicin showed no
noticeable changes in adhesive force compared to the other
groups. All cells treated with allicin or drugs were softer than the
control cells. When the cells were treated with the combination of
flucytosine + allicin, the stiffness of the cells increased compared to
that of cells treated with flucytosine alone.
Discussion
In this study, we analyzed the antifungal effects of allicin
quantitatively and qualitatively by measuring the changes in
morphology and biophysical properties of C. albicans. In addition,
we evaluated the activity of allicin in combination with AmB and
flucytosine. C. albicans cells were not seriously damaged when
treated with allicin alone. However, when allicin was used in
combination with antifungal drugs, the cells were seriously
damaged or destroyed. In particular, the cells treated with AmB
Antifungal Activity of Allicin
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+ allicin. The outer membranes of cells treated with AmB + allicin
were completely destroyed and the adhesive force of these cells was
higher than that of control cells.
Allicin has been reported to have antibacterial, antifungal,
antiparasite, and antiviral activity [6–16]. A broad range of
bacteria, including E. coli, Staphylococcus aureus, Streptococcus pyogenes,
Proteus mirabilis, Pseudomonas aeruginosa, Acetobacter baumanii, Klebsiella
pneumoniae, Enterococcus faecium, Myco-bacterium tuberculosis, H. pylori,
Salmonella, Clostridium, and Shigella show allicin sensitivity.
Although allicin is a very useful natural compound for treating
fungal infections, its high MIC prevents its effective use in a
clinical setting. Pure allicin has been shown to have antifungal
activity against species of Candida, Cryptococcus, Trichophyton,
Epidermophyton, and Microsporum at concentrations of 1.57 ,
6.25 mg/mL [17]. These are very high concentrations compared
to those of antifungal drugs; for example, the MIC50 and MIC90
of AmB against C. albicans is 0.5 and 1.0 mg/mL, respectively
[19]. One garlic bulb contains 6 , 14 mg/g of alliin, which is
transformed into allicin by allinase [20]. Therefore, it will be
more effective to use allicin in combination with conventional
antifungal agents rather than allicin used alone. In this manner,
the efficacy of conventional drugs can be enhanced with the
minimal concentrations.
The synergic effects of allicin was investigated with two drugs
of AmB and flucytosine, which used only a small amount
(MIC10) to detect from the early stage to the final stage of the
cell death process. There was no difference in the cell viability
of the cells treated with AmB + allicin and the cells treated with
flucytosine + allicin. However, when cells were characterized
according to the CDP, we found that there were more cells at
CDP0 in the group treated with flucytosine + allicin than in the
group treated with AmB + allicin. However, there were more
CDP1 cells in the group treated with AmB + allicin than the
Figure 1. Cell viability of C. albicans treated with allicin and antifungal drugs. (a) The viability of C. albicans as a function of allicin
concentration. The concentration of allicin was increased from 0 (control) to 5 mg/mL. (b) Cell viability as a function of treatment conditions. C.
albicans cells were treated with allicin alone, one kind of drug (AmB, flucytosine), and the combinations of AmB + allicin, flucytosine + allicin, and AmB
+ flucytosine + allicin.
doi:10.1371/journal.pone.0038242.g001
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increased at CDP2 and CDP3. As shown in the AFM images,
the cells treated with AmB showed changes in the outer
membrane, and were seriously damaged when allicin was added
[21]. These results indicate that the antifungal efficacy of AmB
is significantly enhanced in the presence of allicin. This result
can be understood by considering the mechanisms of action of
both AmB and allicin. AmB is thought to bind to ergosterol and
then destroy the integrity of the fungal membrane [22]. In
addition, AmB is thought to induce ROS-based oxidative
damage [23]. Correlated with this mechanism, it was recently
reported that allicin could increases the antifungal activity of
Cu
2+ [16]. Cu
2+ is toxic to living cells because it accelerates the
generation of ROS. Living cell membranes are damaged by
ROS that oxidize proteins; in addition, ROS can damage DNA
and RNA. Akiar et al. reported that the lethal effects of Cu
2+
Figure 2. SEM images of C. albicans treated with allicin or antifungal drugs for 24 hours. (a) Control cells. The images shown in (b)–(g) are
of cells treated with allicin alone, AmB, flucytosine, AmB + allicin, flucytosine + allicin, and AmB + flucytosine + allicin, respectively.
doi:10.1371/journal.pone.0038242.g002
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antifungal activity of AmB was likely enhanced by allicin
because allicin increased the permeability of the cell membrane.
In contrast, the efficacy of flucytosine was not much improved
by allicin co-treatment in the context of morphological changes.
This result can be explained by considering flucytosine’s
mechanism of action. Flucytosine acts mainly on the RNA
and DNA of fungi. Flucytosine alters the amino-acylation of
tRNA and disturbs the building of essential proteins due to its
incorporation into fungal RNA. It also inhibits fungal DNA
synthesis after it is converted into 5-fluorodeoxyuridinemono-
phosphate [24]. Cells treated with this antifungal agent were
damaged initially from the interior, as indicated by membrane
collapse. Flucytosine and allicin act on different parts of the cell
Figure 3. AFM images of C. albicans treated with allicin or antifungal drugs for 24 hours. (a) Control cells. The images shown in (b) – (g) are
of cells treated with allicin alone, AmB, flucytosine, AmB + allicin, flucytosine + allicin, and AmB + flucytosine + allicin, respectively. The arrows indicate
significant morphological changes.
doi:10.1371/journal.pone.0038242.g003
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synergistic effects.
The adhesive force is the strength of the interaction between the
cell membrane and the AFM tip, and it is very sensitive to the
properties of the membrane. Cells treated with flucytosine had less
adhesive force than control cells, consistent with the results
reported in our previous study [18]. While, the cells treated with
AmB showed an opposite trends to our previous results, the
adhesive force was increased by the treatment with AmB as in a
previous study, but was decreased in this work [18]. Adhesive force
generally decreases during cell death [25]. In the previous study,
we assumed that the increased adhesive force measured after
treatment of cells with AmB was due to secretion that occurred
after destruction of the cell membrane and not due to an
interaction between the cell membrane and the AFM tip. The
decreased adhesive force of cells treated with AmB demonstrates
that our assumption was correct. As shown in Fig. 3(b), because the
concentration of AmB was low (MIC10), most cells were at CDP0
while the other cells just started showing morphological changes.
AmB treatment did not result in the destruction of the cell
membrane, and therefore the adhesive force of these cells
decreased as was observed for the other treated cells. However,
Figure 4. Clearing assays with AmB (a), flucytosine (b), allicin (c), AmB + allicin (d), flucytosine + allicin (e), and AmB + flucytosine +
allicin (f). Spot number 1 indicates the control sample. The spots numbered 2, 3, and 4 correspond to antifungal treatments with the concentrations
of MIC10610
21, MIC10, and MIC90, respectively.
doi:10.1371/journal.pone.0038242.g004
Table 1. The diameter of clearance zones according to treatment condition.
Diameter of clearance zones (cm)
Spot number
(Concentrations)
1
(Control)
2
(MIC10610
21)
3
(MIC10)
4
(MIC90)
Amphotericin B 0.48760.012 0.92660.047 1.23660.053
Flucytosine 0.65360.018 1.08360.058
Allicin 0.75760.041 0.93160.029
Amphotericin B + Allicin 0.72760.047 1.06760.012 1.28260.012
Flucytosine + Allicin 0.93160.006 1.16660.105
Amphotericin B + Flucytosine +Allicin 1.00560.017 1.3660.047
doi:10.1371/journal.pone.0038242.t001
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membranes of the cells burst, as shown in Fig. 3(e), resulting in
secretion of internal molecules. This increased the adhesive force
of these cells compared to cells treated with AmB alone.
In conclusion, allicin has antifungal activity but a very high
MIC against pathogenic fungi. However, the antifungal activity of
the conventional drug, AmB, was significantly enhanced in the
presence of allicin, because of the similar mechanism of action of
these two compounds. Therefore, the combination of allicin and
an antifungal drug may be effective at treating fungal infections
with minimal side-effects.
Materials and Methods
Culture and Preparation of C. albicans
C. albicans cells (ATCC, Rockville, MD, USA) were maintained
in Sabouraud broth and incubated at 37uC for 24 hours in a
shaking incubator at 180 rpm. The cells were centrifuged at
2500 rpm for 15 minutes and then washed in calcium-,
magnesium-free phosphate-buffered saline (DPBS).
Table 2. The normalized number of cells at different cell death phases (CDP) according to treatment condition.
Normalized number of cells (%)
Treatment condition CDP0 CDP1 CDP2 CDP3
Control 93.6164.47 1.6862.38 2.8461.54 1.8560.55
Amphotericin B 70.4965.86 5.4760.97 13.5760.24 10.4664.64
Flucytosine 71.1664.69 7.4462.94 1.9060.07 3.8861.66
Allicin 79.4563.92 5.8363.22 8.3863.23 6.3263.91
Amphotericin B + Allicin 49.97612.23 13.4364.37 18.5361.83 18.0566.02
Flucytosine + Allicin 72.49612.70 10.2262.99 7.9365.98 9.3469.72
Amphotericin B + Flucytosine +Allicin 52.5162.60 9.8666.78 24.0763.87 13.5560.31
The CDP was assessed by analyzing SEM and AFM images of cells treated for 24 hours.
doi:10.1371/journal.pone.0038242.t002
Figure 5. Changes in the biophysical properties of C. albicans according to treatment condition. (a) Changes in the adhesive force
between the cells surface and the AFM tip and (b) changes in the stiffness of the cell membrane.
doi:10.1371/journal.pone.0038242.g005
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Allicin was purchased from AllimaxH (Allimax Nutraceuticals,
Chicago, USA) at a guaranteed 100% yield of pure stabilized
allicin extract. The minimum inhibitory concentrations (MIC10)o f
allicin were calculated by measuring cell viability at different
concentrations of allicin ranging from 0 to 5 mg/mL. The MIC10
of the antifungal agents amphotericin B and flucytosine were
determined according to the method of Brito et al. [19]. C. albicans
were grouped by treatment conditions as follows: control, allicin,
AmB, flucytosine, allicin + AmB, allicin + flucytosine, allicin +
AmB + flucytosine. For all groups, cell viability was evaluated by
Trypan blue staining after 0, 6, 12, 18, and 24 hours of treatment.
Details of how the cell viability measurements were performed are
described in a previous study [18].
Clearing Assay
Candida cells (1610
6 cells/ml) were inoculated onto Sabouraud
dextrose agar plates. Antifungal-containing discs (AmB, flucyto-
sine, allicin, AmB + allicin, flucytosine + allicin, AmB + flucytosine
+ allicin) were introduced onto the plate at three different
concentrations (MIC10610
21, MIC10, and MIC90). The MIC10
and MIC90 of allicin were 1 mg/ml and 128 mg/ml, respectively
[16]. The MIC10 and MIC90 of AmB and Flu were 0.1 mg/ml and
1 mg/ml, respectively [26]. Plates were incubated at 37uC for 24
hours, and then photographed.
SEM and AFM Observations
C.albicanscellswerefixedin2.5%glutaraldehydein0.1 MPBSfor
30 minutes and washed with 0.1 M PBS. To dehydrate the cells,
collected cells were immersed in 100% ice-cold acetone for 10
minutes.ForSEMmeasurements,C.albicansweresmearedonasilver
stub like a thin film, and the samples were gold-coated by cathodic
spraying (Polaron gold). The SEM observations were made using a
Cambridge Instruments S250 SEM. All observations were per-
formed under the conditions of EHT=20.00 kV, WD=9.5 mm,
SignalA=SE1.Nanoscalemorphologicalchangesandthebiophys-
icalpropertiesofC.albicanswereinvestigatedbyusinganAFMsystem
(Surface Imaging Systems, Herzogenrath, Germany). All images
were measured in contact mode (Budget Sensor, Bulgaria) with a
resolution of 2566256 pixels and a scan speed of 0.2 lines/sec. The
probes used for imaging had a resonance frequency of 13 kHz
(64 kHz), a force constant of 0.2 N/m (60.14 N/m), a cantilever
lengthof450 mm(610 mm),acantileverwidthof38 mm(65 mm),a
cantileverthicknessof2 mm(61 mm),atipradiusof5 nm(61 nm),
and a tip heightof 17 mm(62 mm).
The stiffness and adhesive forces of the cells were determined
by force-distance curve (FD) measurements. The FD curves
were measured at the loading rate of 1 mm/s. The elasticity
of C. albicans was calculated according to the equation
1=kcell~1
keffective{1=kcantilever where keffective and kcantilever were
determined from the slope of the linear region of approaching
curve for C. albicans and a slide glass, respectively [27].
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